In conclusion, our results extend previous findings on the role of S1P in the regulation of the immune response in CF as well as on its toxic effects on fungal growth, thus supporting the development of dual-species SPL inhibitors as a combined anti-inflammatory and antifungal strategy in CF. This evidence concerns the gene SGPL1 and cystic fibrosis.